# A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

> **NCT04730349** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 15 (actual)

## Conditions studied

- Ependymoma
- Ewing Sarcoma
- High-grade Glioma
- Leukemia and Lymphoma
- Medulloblastoma
- Miscellaneous Brain Tumors
- Miscellaneous Solid Tumors
- Neuroblastoma
- Relapsed, Refractory Malignant Neoplasms
- Rhabdomyosarcoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** NKTR-214

## Key facts

- **NCT ID:** NCT04730349
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-03
- **Primary completion:** 2022-06-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730349, "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04730349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*